The first patient has been dosed in a Phase I clinical trial of breast cancer treatment ABY-271.

ABY-271 is a radiotherapeutic candidate being assessed as a potential treatment for HER2-positive metastatic breast cancer. The Phase I study evaluating the safety, tolerability and biodistribution of ABY-271 is a first-in-human open-label, two-stage, randomised trial being conducted in Sweden and Germany. The first patient was enrolled at Uppsala University Hospital in Sweden. 

ABY-271 is an Affibody molecule that targets HER2-expressing tumours and is labelled with the radioisotope lutetium-177, which emits cytotoxic beta radiation, exerting irreversible damage to the tumour cells upon binding.